Oct 30, 2024 4:15pm EDT Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
Oct 02, 2024 4:05pm EDT Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
Sep 03, 2024 8:00am EDT Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
Jul 30, 2024 8:00am EDT Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Jul 17, 2024 8:00am EDT Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
Jun 11, 2024 8:20am EDT Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
May 06, 2024 8:00am EDT Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
Apr 30, 2024 8:00am EDT Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
